Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population"

Ann Neurol. 2020 Jan;87(1):155. doi: 10.1002/ana.25633. Epub 2019 Nov 14.

Authors

Inge M W Verberk^{1

2}, Charlotte E Teunissen², Wiesje M Van der Flier¹

Affiliations

¹ Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
² Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.

PMID: 31675120
DOI: 10.1002/ana.25633

No abstract available

Publication types

Letter
Comment

MeSH terms

Alzheimer Disease*
Amyloid
Amyloid beta-Peptides
Amyloidosis*
Humans
Plasma

Substances

Amyloid
Amyloid beta-Peptides